Doxorubicin (Adriamycin)-Induced Ferroptosis Requires ACSL4 Activation and Acot1 Suppression During Cardiac Myocyte Damage

Explore how Doxorubicin triggers ferroptosis in cardiomyocytes via ACSL4 activation, Acot1 suppression, and lipid peroxidation for cardioprotective targets.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    However, clinical regimens producing plasma concentrations between 0.2 μM and 1.0 μM trigger early cytotoxic kinetics that do not align with classical apoptosis [1][2].
  • 2
    The commitment of cardiomyocytes to ferroptosis is governed by the structural remodeling of sarcoplasmic phospholipid bilayers [1][4].
  • 3
    Deprived of Acot1-mediated cleavage, arachidonoyl-CoA and adrenoyl-CoA intermediates avoid metabolic degradation and accumulate unchecked in the sarcoplasm [1][6].
  • 4
    Superoxide dismutation produces excessive hydrogen peroxide (\uce{H2O2}), which degrades ferritin complexes and mitochondrial heme-containing proteins, elevating sarcoplasmic labile iron (\uce{Fe^2+}) levels [1][6].
  • 5
    Mitigating doxorubicin-induced cardiotoxicity requires pharmacological strategies that decouple ACSL4 activation or re-establish acyl-CoA hydrolysis [1][6].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
MOA PATHWAY — Doxorubicin (Adriamycin) P=Phospho | ->=Activate | -|=Inhibit EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS Doxorubicin 0.5 μM SLC7A11 ACSL4 P Acot1 LPCAT3 PE-18:0/20:4-OOH GPX4 Fe 2+ ROS TOP2B NRF2 / p53 P
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin)-Induced Ferroptosis.

A multi-compartment signaling pathway illustrating the cardiac myocyte sarcoplasm, mitochondrial membrane, and nucleus under Doxorubicin exposure. In the cytosol, Doxorubicin downregulates Acot1 while upregulating ACSL4, which esterifies arachidonic acid (C20:4) into AA-CoA for LPCAT3-mediated membrane insertion into PE-AA. Within the mitochondria, Complex I-driven Doxorubicin quinone redox cycling generates superoxide and liberates labile Fe2+, accelerating Fenton-driven oxidation of PE-AA into lethal PE-AA-OOH while PRMT4-mediated Nrf2 restriction represses GPX4 and SLC7A11 defenses, causing sarcolemmal pore formation and myocyte death.

Divergence from Classical Topoisomerase IIβ Cleavage: Ferroptotic Rupture in Anthracycline Myopathy

The clinical management of anthracycline chemotherapy has long centered on TOP2B-mediated DNA double-strand breaks as the primary driver of cardiac injury [1]. However, clinical regimens producing plasma concentrations between 0.2 μM and 1.0 μM trigger early cytotoxic kinetics that do not align with classical apoptosis [1][2]. In HL-1 murine atrial cardiomyocytes and H9c2 rat cardiomyoblasts, challenge with 0.5 μM doxorubicin induces pronounced cell detachment and viability loss within 16 to 24 hours [2][3]. Co-administration of the pan-caspase antagonist Z-VAD-FMK at concentrations up to 50 μM fails to reverse cell death, whereas lipophilic radical-trapping antioxidants such as Ferrostatin-1 (1 μM to 5 μM) or Liproxstatin-1 (200 nM to 1 μM) confer near-complete cytoprotection [2][3]. Similarly, suppressing necroptosis using Necrostatin-1 or targeting pyroptosis fails to mitigate early troponin release in cultured cardiomyocytes [2].

Transmission electron microscopy of left ventricular biopsies derived from doxorubicin-treated rodents displays canonical ferroptotic morphology [1][2]. Affected cardiomyocytes exhibit diminished mitochondrial volume, condensed and disrupted outer mitochondrial membranes, and vanishing cristae, while maintaining structurally intact nuclear envelopes devoid of apoptotic peripheral chromatin condensation [1][2]. This distinct cytopathology stems from accelerated membrane lipid peroxidation rather than endonucleolytic DNA fragmentation [1]. Comparative molecular profiling under standardized anthracycline exposure establishes distinct mechanistic boundaries between ferroptosis, caspase-dependent apoptosis, and necroptosis in cardiac tissue, as summarized in Table 1 below.

ACSL4-Catalyzed Esterification of Polyunsaturated Fatty Acids in the Cardiac Sarcoplasm

The commitment of cardiomyocytes to ferroptosis is governed by the structural remodeling of sarcoplasmic phospholipid bilayers [1][4]. Acyl-CoA synthetase long-chain family member 4 (ACSL4) functions as the key enzyme initiating this cascade by esterifying free polyunsaturated fatty acids (PUFAs) with coenzyme A [1][4]. ACSL4 displays strict substrate specificity toward arachidonic acid (C20:4, \u03c9-6) and adrenic acid (C22:4, \u03c9-6), exhibiting Km values below 5 μM for these long-chain polyunsaturates [1]. Upon anthracycline exposure, ACSL4 undergoes rapid transcriptional and post-translational upregulation in myocardial tissue within 6 to 12 hours [1][5]. In AC16 human cardiomyocyte models, doxorubicin exposure at 1 μM produces a three- to fourfold induction of ACSL4 protein expression, directly accelerating the esterification rate of free arachidonate into arachidonoyl-CoA [5].

Following ACSL4-dependent activation, lysophospholipid acyltransferase 3 (LPLAT3/LPCAT3) incorporates arachidonoyl-CoA and adrenoyl-CoA intermediates into membrane glycerophospholipids, predominantly phosphatidylethanolamines (PE) [1]. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) lipidomic profiling reveals that cardiac sarcoplasmic membranes accumulate substantial amounts of 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (PE-18:0/20:4) within 12 hours of doxorubicin challenge [1][5]. These sn-2 esterified polyunsaturated moieties feature readily accessible bis-allylic methylene carbons that possess low carbon-hydrogen bond dissociation energies (~322 kJ/mol) [1]. Consequently, the selective enrichment of PE-arachidonoyl species catalyzed by ACSL4 provides the obligate chemical substrate required for non-enzymatic and enzymatic autoxidation chains, rendering the cardiac sarcolemma vulnerable to biophysical collapse [1][4].

Acot1 Depletion Eliminates Free Fatty Acid Shunting and Elevates the Acyl-CoA Precursor Pool

Under normal physiological conditions, the heart relies on long-chain fatty acid β-oxidation to meet high baseline energetic demands [6][7]. Cytosolic acyl-CoA thioesterase 1 (Acot1) acts as a critical counter-regulatory metabolic valve by hydrolyzing fatty acyl-CoAs back into free fatty acids and coenzyme A [1][7]. By cleaving long-chain substrates, Acot1 prevents the abnormal accumulation of intracellular acyl-CoA pools and restricts unnecessary lipid intermediate incorporation into cellular structural membranes [6][7]. However, myocardial tissue challenged with therapeutic concentrations of doxorubicin exhibits a steep, progressive decline in Acot1 mRNA and protein expression [1][6]. In murine ventricles, single-dose doxorubicin administration (15 mg/kg) provokes a marked loss of cardiac Acot1 expression within 24 hours [6].

The loss of Acot1 activity halts the cytosolic acyl-CoA hydrolysis shunt [1][7]. Deprived of Acot1-mediated cleavage, arachidonoyl-CoA and adrenoyl-CoA intermediates avoid metabolic degradation and accumulate unchecked in the sarcoplasm [1][6]. This sustained elevation of the acyl-CoA precursor pool exerts mass-action pressure directly toward membrane esterification pathways [1]. Knockdown of Acot1 via targeted small interfering RNA in neonatal cardiomyocytes exacerbates doxorubicin sensitivity, elevating basal lipid peroxidation and precipitating spontaneous ferroptotic rupture [6][7]. Conversely, forcing Acot1 expression preserves cellular viability, proving that Acot1 suppression acts synergistically with ACSL4 activation to fuel toxic phospholipid assembly [1][6].

Mitochondrial Labile Iron Expansion and Iron-Catalyzed Peroxidation Chains

The metabolic accumulation of polyunsaturated phosphatidylethanolamines requires an iron-dependent catalyst to execute membrane peroxidation [1][2]. Doxorubicin possesses a planar hydroxyanthraquinone aglycone ring system capable of univalent electron reduction [1]. Inside the cardiomyocyte sarcoplasm and mitochondrial inner membrane, electron transport chain Complex I and NAD(P)H oxidoreductases transfer electrons to the doxorubicin quinone nucleus, producing a reactive semiquinone radical intermediate [1]. Under aerobic conditions, this semiquinone autoxidizes by transferring its acquired electron to molecular oxygen, generating superoxide anions (\uce{O2^{\u2022-}}) and regenerating the parent quinone core to sustain redox cycling [1].

Superoxide dismutation produces excessive hydrogen peroxide (\uce{H2O2}), which degrades ferritin complexes and mitochondrial heme-containing proteins, elevating sarcoplasmic labile iron (\uce{Fe^2+}) levels [1][6]. The expanded \uce{Fe^2+} pool coordinates with doxorubicin molecules, assembling ternary drug-iron-membrane complexes adjacent to polyunsaturated fatty acyl chains [1]. Through classical Fenton chemistry, \uce{Fe^2+} reacts with \uce{H2O2} to form highly destructive hydroxyl radicals (\uce{^{\u2022}OH}), which perform bis-allylic hydrogen abstraction on PE-arachidonoyl species [1][2]. The resulting carbon-centered phospholipid radicals capture molecular oxygen to produce phospholipid peroxyl radicals (\uce{PL-OO^{\u2022}}), triggering sustained auto-catalytic propagation [1]. In tandem, doxorubicin causes marked depletion of glutathione peroxidase 4 (GPX4) and downregulates the cystine/glutamate antiporter SLC7A11 [1][7]. The secondary collapse of GPX4 halts the reduction of toxic phospholipid hydroperoxides (\uce{PL-OOH}) into harmless phospholipid alcohols (\uce{PL-OH}), driving irreversible sarcolemmal pore formation [1].

Pharmacological Reversal Through Targeted Lipid Editing and Enzyme Modulation

Mitigating doxorubicin-induced cardiotoxicity requires pharmacological strategies that decouple ACSL4 activation or re-establish acyl-CoA hydrolysis [1][6]. In C57BL/6 male mice subjected to acute cardiotoxic regimens (20 mg/kg intraperitoneally), targeted pharmacological suppression of ACSL4 using small-molecule antagonists such as PRGL493 (10 mg/kg) or Rosiglitazone (10 mg/kg) reduces myocardial malondialdehyde (MDA) adducts by more than 50% [4][5]. Rosiglitazone acts as a competitive ACSL4 inhibitor, preventing arachidonoyl-CoA formation and attenuating doxorubicin-induced left-ventricular ejection fraction (LVEF) deterioration [5]. In cultured cardiomyocytes, ACSL4 inhibition restores cell survival, demonstrating that halting polyunsaturated fatty acid esterification blocks downstream membrane degradation [4][5].

Genetic complementation strategies that re-establish acyl-CoA homeostasis further confirm this therapeutic logic [1][6]. Delivering human Acot1 via cardiotropic adeno-associated virus serotype 9 (AAV9) under control of the cardiac troponin T promoter prevents toxic acyl-CoA accumulation in treated rodents [2][6]. Rescuing Acot1 activity suppresses C11-BODIPY 581/591 fluorophore oxidation and maintains normal sarcoplasmic reticulum calcium handling [3][6]. By comparison, dexrazoxane—the only clinically approved cardioprotectant against anthracyclines—acts downstream via intracellular iron chelation and topoisomerase IIβ antagonism [6]. Direct genetic or chemical disruption of the ACSL4-Acot1 axis prevents the synthesis of peroxidation substrates at the source, offering cardioprotection that shields myocardial structural integrity without blunting the chemotherapeutic efficacy of doxorubicin [1][6].

Table 1. Comparative Mechanistic and Pharmacological Profiles of Doxorubicin-Induced Cardiomyocyte Death Modalities

Biological Parameter / ReadoutFerroptosis (ACSL4/Acot1 Axis)Classical Apoptosis (TOP2B-Mediated)Necroptosis (RIPK1/RIPK3/MLKL Axis)Pharmacological Significance
Primary Molecular DriverACSL4 upregulation and Acot1 downregulationTOP2B-DNA cleavage complexesRIPK1/RIPK3 necrosome assemblyDefines specific upstream intervention targets
Key Lethal EffectorPE-AA-OOH lipid hydroperoxidesCaspase-3/Caspase-7 executionersPhosphorylated MLKL oligomersDistinguishes membrane lipid oxidation from proteolysis
Mitochondrial UltrastructureShrunken, condensed cristae, ruptured outer membraneCytochrome c release, preserved outer shapeSwollen matrix, early outer membrane ruptureElectron microscopy gold standard diagnostic feature
Response to Z-VAD-FMKNo protection observed (0% rescue)Near-complete viability rescue (>80%)Sensitization toward death pathwayPharmacological rule-out of caspase dependency
Response to Ferrostatin-1Complete cytoprotection (EC50 ~120 nM)No protection observed (0% rescue)No protection observed (0% rescue)Confirms lipophilic radical scavenging requirement
Response to ACSL4 AntagonistsSignificant suppression of lipid ROSNo direct inhibitory effectNo direct inhibitory effectConfirms specificity of acyl-CoA lipid editing

Note: Pharmacological benchmarking parameters based on in vitro HL-1/H9c2 cardiomyocytes and in vivo rodent cardiotoxicity models evaluating cell survival, ultrastructure, and inhibitor sensitivity.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

What is the significance of Divergence from Classical Topoisomerase IIβ Cleavage: Ferroptotic Rupture in Anthracycline Myopathy?Mechanism of Action

The clinical management of anthracycline chemotherapy has long centered on TOP2B-mediated DNA double-strand breaks as the primary driver of cardiac injury [1]. However, clinical regimens.

What is the significance of ACSL4-Catalyzed Esterification of Polyunsaturated Fatty Acids in the Cardiac Sarcoplasm?Pharmacological Potency

The commitment of cardiomyocytes to ferroptosis is governed by the structural remodeling of sarcoplasmic phospholipid bilayers [1][4]. Acyl-CoA synthetase long-chain family member 4 (ACSL4) functions.

References

  1. [1]. Wu L, et al. JACC: Basic to Translational Science. 2024;9(6):811-826.
  2. [2]. Shi Y, et al. Theranostics. 2025;15(11):4931-4954. [IF: 13.3]
  3. [7]. Zhuang X, et al. Advanced Science. 2025;12(23).
  4. [5]. Wu M, et al. Chinese Medical Journal. 2025;138(19):2498-2510. [IF: 7.3]
  5. [6]. Cheng L, et al. iScience. 2024;27(10):111005. [IF: 4.1]
  6. [3]. Wang T, et al. Reviews in Cardiovascular Medicine. 2023;24(11). [IF: 1.9]
  7. [4]. Famurewa AC, et al. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;398(5):4747-4778.